Evidence-Based Complementary and Alternative Medicine

Review Article

Tianma Gouteng Yin as Adjunctive Treatment for Essential Hypertension: A Systematic Review of Randomized Controlled Trials

Table 5

Analyses of systolic blood pressure.
Trials MD [95% CI]P Value
TGY plus ACEI versus ACEI   
 modified TGY plus captopril versus captopril1−9.70 [−11.80, −7.60]<0.00001
 TGY plus captopril versus captopril1−6.20 [−7.03, −5.37]<0.00001
 TGY plus captopril versus captopril1−8.76 [−10.02, −7.50]<0.00001
 TGY plus captopril versus captopril1−5.30 [−9.88, −0.72]0.02
 TGY plus captopril versus captopril1−6.65 [−6.89, −6.41]<0.00001
Meta-Analysis5−6.71 [−6.94, −6.49]<0.00001
TGY plus CCB versus CCB   
 modified TGY plus nifedipine sustained release tablets versus nifedipine sustained release tablets1−13.00 [−14.48, −11.52]<0.00001
 modified TGY plus amlodipine besylate versus amlodipine besylate1−12.60 [−13.69, −11.51]<0.00001
 TGY plus nifedipine sustained release tablets versus nifedipine sustained release tablets1−10.68 [−11.62, −9.74]<0.00001
Meta-Analysis3−12.25 [−13.52, −10.54]<0.00001
TGY plus diuretics versus diuretics   
 modified TGY plus hydrochlorothiazide versus hydrochlorothiazide10.28 [−0.72, 1.28]0.58
Meta-Analysis10.28 [−0.72, 1.28]0.58
TGY plus ARB versus ARB   
 TGY plus telmisartan versus telmisartan1−3.70 [−3.78, −3.62]<0.00001
Meta-Analysis1−3.70 [−3.78, −3.62]<0.00001
TGY plus “CCB + ACEI” versus “CCB + ACEI”   
 modified TGY plus amlodipine besylate and lisinopril versus amlodipine besylate and lisinopril1−11.03 [−12.72, −9.34]<0.00001
Meta-Analysis1−11.03 [−12.72, −9.34]<0.00001